NCT03078855View on ClinicalTrials.gov

A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma

PHASE3CompletedINTERVENTIONAL
Enrollment

211

Participants

Timeline

Start Date

September 7, 2017

Primary Completion Date

July 21, 2023

Study Completion Date

July 2, 2024

Conditions
Follicular LymphomaSmall Lymphocytic LymphomaMarginal Zone LymphomaMucosal-Associated Lymphoid Tissue Lymphoma
Interventions
DIETARY_SUPPLEMENT

Vitamin D

vitamin D3 2,000 IU daily

BIOLOGICAL

Rituximab

Administered weekly x 4

OTHER

Placebo

methylcellulose

Trial Locations (7)

10021

Weill Cornell Medical College, New York

14642

James P. Wilmot Cancer Institute at University of Rochester Medical Center, Rochester

30322

Emory University, Winship Cancer Institute, Atlanta

33136

University of Miami, Miami

52242

University of Iowa, Iowa City

63130

Washington University, St Louis

77030

The University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Cancer Institute (NCI)

NIH

lead

Jonathan Friedberg

OTHER

NCT03078855 - A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter